Lyudmila A. Bazhenova, MD
Articles
Outcomes of Larotretinib Confirmed in TRK Fusion-Positive Lung Cancer
January 29th 2021Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the currently available treatment strategies for patients with non-driver non–small cell lung cancer.
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses ongoing and remaining challenges in the field of non-driver non–small cell lung cancer, as well as a look toward the future treatment landscape.
